ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / VOGX
BNTC (30) IRD (23) PRLD (33) ENTA (20) ⌘ Pro Terminal →

Vogenx Inc (VOGX) — RQD Stock Rating Cockpit

$20.74 +2.42% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $20.79

Vogenx Inc (VOGX) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $300.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VOGX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VOGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Vogenx Inc (NASDAQ: VOGX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $20.74 (+2.42% 1D, market cap $300.8M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VOGX compare to BNTC and IRD in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VOGX carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, BNTC (Benitec Biopharma Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $304.9M) and IRD (Opus Genetics Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $305.3M). Among the 5-stock peer group, VOGX leads on earnings multiple (N/A) while BNTC leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VOGX?
▼

Per VOGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001903784), Vogenx Inc generated $286.1K in revenue, $0 in net income, and $0 in free cash flow against $681.2K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $20.79 (+0.25%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 842.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510045
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D+
Cash (10)Whales (5)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.8% Base Target
$40 Bull$20 Base$15 Bear
📬 FREE VOGX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VOGX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY VOGX SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 842.3% FCF Margin ($8.4M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
37
Grade E$16.76+11.9% Next Q
Q2 (-2Q)
40
Grade D$18.75+2.2% Next Q
Q3 (-1Q)
42
Grade D$19.16+8.2% Next Q
Current
45
Grade D$20.74-6.3% Hist 90D α
Trajectory: E (37) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a VOGX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While VOGX currently carries a cautious 45/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.28) and Max Pain ($21.78) forces dealer call-delta covering toward $40.33.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VOGX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VOGX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 45%NO 55%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
52.930 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE31% OF RANGE
L: $13$20.74H: $38
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 10 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

2-of-3 Quant Analysts Bearish Warning on VOGX

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (50)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (37)

14/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like VOGX
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VOGX)

  • ✓Walkthrough of VOGX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
VOGX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +59.54%▲ ASCENDING CHANNEL
2026-11-03O $19.92H $20.74L $19.92C $20.74VOL 45.1K
RES: $43.89SUP: $15.24SMA50: $24.28SMA200: $23.70
$40.19$32.81$25.43$18.04$10.66RES $43.89SUP $15.24$20.742026-08-122026-09-012026-09-232026-10-132026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VOGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VOGX Butterfly Map → + Track VOGX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on VOGX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VOGX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VOGX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VOGX)

Health Care Rank #367 of 1015 ⚔️ BNTC vs VOGX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VOGX vs. BNTC, IRD, PRLD, ENTA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Vogenx Inc (VOGX) ranks #367 by composite RQD confidence (45/100, grade D) and #518 by equity capitalization ($300.8M). Within this direct 5-issuer industry benchmark cohort, VOGX leads on earnings valuation at N/A trailing P/E, while BNTC leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VOGX currently leads its immediate peer cohort in composite quantitative strength at 45/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
VOGX ACTIVE
Vogenx Inc
D 45/100 — — — +2.42% $300.8M Benchmark Subject
BNTC
Benitec Biopharma Inc.
E 30/100 — — -35.0% -2.86% $304.9M /bntc-vs-vogx →
IRD
Opus Genetics Inc.
E 23/100 — — -35.0% +0.82% $305.3M /ird-vs-vogx →
PRLD
Prelude Therapeutics Incorporated
E 33/100 — — -35.0% -1.03% $309.6M /prld-vs-vogx →
ENTA
Enanta Pharmaceuticals Inc.
E 20/100 — — -35.0% -2.61% $311.9M /enta-vs-vogx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001903784 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vogenx Inc (VOGX) reported GAAP revenue of $286.1K , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, VOGX closed FY2025 with $681.2K in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $286.1K $0 — — $681.2K —

3. VOGX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VOGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Vogenx Inc (NASDAQ: VOGX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $20.74 (+2.42% 1D, market cap $300.8M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

How does VOGX compare to BNTC and IRD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VOGX carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, BNTC (Benitec Biopharma Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $304.9M) and IRD (Opus Genetics Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $305.3M). Among the 5-stock peer group, VOGX leads on earnings multiple (N/A) while BNTC leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VOGX?

Per VOGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001903784), Vogenx Inc generated $286.1K in revenue, $0 in net income, and $0 in free cash flow against $681.2K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VOGX trading relative to its 50-day, 200-day, and 52-week technical levels?

VOGX last traded at $20.74 (+2.42% on volume of 152,314 shares), positioning the stock -14.58% below its 50-day simple moving average ($24.28) and -12.49% below its 200-day simple moving average ($23.70). Across its 52-week range of $12.95 to $38.41, VOGX sits at the 30.6% percentile with a 14-day RSI of 52.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($18.15 to $23.33).

Direct Sub-Reports: VOGX RQD Cockpit VOGX 12M Forecast VOGX Earnings & Move VOGX Dividends & DRIP VOGX Insiders & 13F VOGX Whale Options VOGX Profit Sankey VOGX News & Why
ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ SEC XBRL & RQD VERIFIED

VOGX — Vogenx Inc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Vogenx Inc (VOGX) earns a live Roarable RQD composite score of 45/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $20.74 (+2.42% 1D, market capitalization $300.8M).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Vogenx Inc (VOGX) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..3B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Vogenx Inc (VOGX) reported $286.1K in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $681.2K in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 45/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $12.95 – $38.41 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Investors should watch high-yield spreads and net liquidity trends as the transmission path, since no supplier or customer bottleneck is recorded in the source data.

  • Key Question #1: Can VOGX sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $286.1K and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is VOGX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

VOGX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Vogenx Inc (VOGX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VOGX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VOGX Bull vs. Bear Conversation Board — What's Your Call at $20.74?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VOGX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on VOGX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $25.72 (+27.0%)
📌 Pinned Debate

Balance sheet holds up relatively well at 13/20 with an Altman Z of 2.5 and Piotroski F of 6/9, and the lead news item flags a green ca

Balance sheet holds up relatively well at 13/20 with an Altman Z of 2.5 and Piotroski F of 6/9, and the lead news item flags a green catalyst in a post-surgery blood-sugar trial.. When you look under the hood at VOGX, Fundamental Cash Engine is 10/20 with 0.0% gross margins and 0.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (5/20) has been quietly accumulating below $38.41. My 12M target is $25.72.

ArenaChamp_24 🐂 BULL

@ShortSeller_Dan Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $17.21 (-15.0%)
Spot @ $20.25

A BEARISH liquidity signal with severity 94 and a Macro Tailwind Score of 18/100 pairs with 0% ROIC and 0% FCF yield, leaving no demons

Here is the bear case nobody on the bull side wants to address on VOGX: A BEARISH liquidity signal with severity 94 and a Macro Tailwind Score of 18/100 pairs with 0% ROIC and 0% FCF yield, leaving no demonstrated cash engine.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE